{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:47:15Z","timestamp":1791924435756,"version":"4.3.4"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,7]],"date-time":"2023-04-07T00:00:00Z","timestamp":1680825600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,7]],"date-time":"2023-04-07T00:00:00Z","timestamp":1680825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key R&D Program of China","doi-asserted-by":"crossref","award":["2022YFA1103300"],"award-info":[{"award-number":["2022YFA1103300"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Key Project of The National Clinical Research Center for Hematological Diseases","award":["2020ZKZC02"],"award-info":[{"award-number":["2020ZKZC02"]}]},{"name":"the Chongqing Natural Science Foundation Innovation Group Science Fund","award":["cstc2021jcyj-cxttX0001"],"award-info":[{"award-number":["cstc2021jcyj-cxttX0001"]}]},{"name":"Special project for talent construction at Xinqiao Hospital","award":["2022XKRC001"],"award-info":[{"award-number":["2022XKRC001"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Chimeric antigen receptor (CAR)-NK cell therapy has the advantages of a low incidence of side effects and a low cost. However, the clinical outcomes are not satisfactory due to limited antitumor effects and a limited proliferative capacity. Recently, progress in CAR-NK cell therapy has been made in NK cell engineering, target design and combination with other agents to treat relapsed or refractory hematological malignancies, especially acute myeloid leukemia and multiple myeloma. This correspondence summarizes the preclinical and clinical updates for universal CAR-NK cell therapy reported at the ASH 2022 annual meeting.<\/jats:p>","DOI":"10.1186\/s13045-023-01435-3","type":"journal-article","created":{"date-parts":[[2023,4,7]],"date-time":"2023-04-07T14:02:45Z","timestamp":1680876165000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["CAR-NK cell therapy for hematological\u00a0malignancies: recent updates from ASH 2022"],"prefix":"10.1186","volume":"16","author":[{"given":"Ruihao","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,7]]},"reference":[{"key":"1435_CR1","doi-asserted-by":"crossref","unstructured":"Lamers-Kok N, Panella D, Georgoudaki A-M, Liu H, \u00d6zkazanc D, Ku\u010derov\u00e1 L, et al. Natural killer cells in clinical development as non-engineered, engineered, and combination therapies. J Hematol Oncol. 2022;15:164.","DOI":"10.1186\/s13045-022-01382-5"},{"key":"1435_CR2","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s40164-022-00341-7","volume":"11","author":"X Wang","year":"2022","unstructured":"Wang X, Yang X, Yuan X, Wang W, Wang Y. Chimeric antigen receptor-engineered NK cells: new weapons of cancer immunotherapy with great potential. Exp Hematol Oncol. 2022;11:85.","journal-title":"Exp Hematol Oncol"},{"issue":"Supplement 1","key":"1435_CR3","doi-asserted-by":"publisher","first-page":"4540","DOI":"10.1182\/blood-2022-163884","volume":"140","author":"L Swanson","year":"2022","unstructured":"Swanson L, Lyon K, Tadros W, Loreti M, Babin T, Blair B, et al. Development of next-generation NK cell optimized chimeric antigen receptors (CARs) for iPSC-derived NK cell therapies targeting both solid and liquid tumors. Blood. 2022;140(Supplement 1):4540\u20131.","journal-title":"Blood"},{"issue":"Supplement 1","key":"1435_CR4","doi-asserted-by":"publisher","first-page":"4560","DOI":"10.1182\/blood-2022-170501","volume":"140","author":"J Reiser","year":"2022","unstructured":"Reiser J, Chan SR, Mathavan K, Sillitti D, Mottershead C, Mattson B, et al. FT555: off-the-shelf CAR-NK cell therapy co-targeting GPRC5D and CD38 for the treatment of multiple myeloma. Blood. 2022;140(Supplement 1):4560\u20131.","journal-title":"Blood"},{"issue":"Supplement 1","key":"1435_CR5","doi-asserted-by":"publisher","first-page":"7378","DOI":"10.1182\/blood-2022-159289","volume":"140","author":"Z Cao","year":"2022","unstructured":"Cao Z, Yang C, Wang Y, Wang C, Wang Q, Ye G, et al. Allogeneic CAR-NK cell therapy targeting both BCMA and GPRC5D for the treatment of multiple myeloma. Blood. 2022;140(Supplement 1):7378.","journal-title":"Blood"},{"issue":"Supplement 1","key":"1435_CR6","doi-asserted-by":"publisher","first-page":"4558","DOI":"10.1182\/blood-2022-169758","volume":"140","author":"N Albinger","year":"2022","unstructured":"Albinger N, Bexte T, Buchinger L, Wendel P, Al-Ajami A, Gessner A, et al. CRISPR\/Cas9 gene editing of immune checkpoint receptor NKG2A improves the efficacy of primary CD33-CAR-NK cells against AML. Blood. 2022;140(Supplement 1):4558\u20139.","journal-title":"Blood"},{"issue":"Supplement 1","key":"1435_CR7","doi-asserted-by":"publisher","first-page":"10288","DOI":"10.1182\/blood-2022-168981","volume":"140","author":"Z Davis","year":"2022","unstructured":"Davis Z, Cichocki F, Felices M, Wang H, Hinderlie P, Juckett M, et al. A novel dual-antigen targeting approach enables off-the-shelf CAR NK cells to effectively recognize and eliminate the heterogenous population associated with AML. Blood. 2022;140(Supplement 1):10288\u20139.","journal-title":"Blood"},{"key":"1435_CR8","doi-asserted-by":"crossref","unstructured":"Caruso S, De Angelis B, Del Bufalo F, Ciccone R, Donsante S, Volpe G, et al. Safe and effective off-the-shelf immunotherapy based on CAR.CD123-NK cells for the treatment of acute myeloid leukaemia. J Hematol Oncol. 2022;15:163.","DOI":"10.1186\/s13045-022-01376-3"},{"issue":"Supplement 1","key":"1435_CR9","doi-asserted-by":"publisher","first-page":"4531","DOI":"10.1182\/blood-2022-157453","volume":"140","author":"B Garrison","year":"2022","unstructured":"Garrison B, Deng H, Yucel G, Frankel NW, Gordley R, Hung M, et al. Senti-202, a selective, off-the-shelf, preclinical CAR-NK cell therapy with CD33 and\/or FLT3 activating CAR, healthy cell protection from endomucin (EMCN) inhibitory CAR and calibrated release IL-15 for hematologic malignancies including AML. Blood. 2022;140(Supplement 1):4531\u20132.","journal-title":"Blood"},{"issue":"Supplement 1","key":"1435_CR10","doi-asserted-by":"publisher","first-page":"2862","DOI":"10.1182\/blood-2022-157663","volume":"140","author":"F Baatz","year":"2022","unstructured":"Baatz F, Herbst J, Meyer J, Schambach A, Maetzig T, Hust M, et al. Bcl11b-edited lymphoid progenitors for the generation of CAR-engineered natural killer-like cells with potent anti-leukemic activity. Blood. 2022;140(Supplement 1):2862\u20133.","journal-title":"Blood"},{"issue":"Supplement 1","key":"1435_CR11","first-page":"7450","volume":"140","author":"R Huang","year":"2022","unstructured":"Huang R, Wen Q, Wang X, Yan H, Ma Y, Mai-Hong W, et al. Off-the-shelf CD33 CAR-NK cell therapy for relapse\/refractory AML: first-in-human. Phase I Trial Blood. 2022;140(Supplement 1):7450\u20131.","journal-title":"Phase I Trial Blood"},{"issue":"Supplement 1","key":"1435_CR12","doi-asserted-by":"publisher","first-page":"4586","DOI":"10.1182\/blood-2022-166994","volume":"140","author":"B Dhakal","year":"2022","unstructured":"Dhakal B, Berdeja JG, Gregory T, Ly T, Bickers C, Zong X, et al. Interim Phase I clinical data of FT576 as monotherapy and in combination with daratumumab in subjects with relapsed\/refractory multiple myeloma. Blood. 2022;140(Supplement 1):4586\u20137.","journal-title":"Blood"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-023-01435-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-023-01435-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-023-01435-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,7]],"date-time":"2023-04-07T14:04:55Z","timestamp":1680876295000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-023-01435-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,7]]},"references-count":12,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1435"],"URL":"https:\/\/doi.org\/10.1186\/s13045-023-01435-3","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,7]]},"assertion":[{"value":"22 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"35"}}